EUVIMEDEUVIMED entdecken
Open Access

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes

Journal of Nuclear Medicine · 2024-06 · 65 (6) · 923-930

DOI: 10.2967/jnumed.123.267023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 18.04.2024. Verfasst von Kévin Hebert und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, Organometallic Compounds. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[177Lu]Lu-DOTATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that overexpress somatostatin receptors. The absorbed doses by limiting organs and tumors can be quantified by serial postinfusion scintigraphy measurements of the γ-emissions from 177Lu. The objective of this work was to explore how postinfusion [177Lu]Lu-DOTATATE dosimetry could influence clinical management by predicting treatment efficacy (tumor shrinkage and survival) and toxicity.

Methods

Patients with GEP-NETs treated with [177Lu]Lu-DOTATATE between 2016 and 2022 and who underwent dosimetry were included. Absorbed doses were calculated for healthy organs (liver, kidneys, bone marrow, and spleen) and tumors using PLANET Dose and the local energy deposition method based on serial posttreatment SPECT/CT. Up to 5 lesions per site were selected and measured on images collected at baseline and 3 mo after treatment end (measurement masked to the somatostatin receptor imaging uptake). For toxicity assessment, laboratory parameters were regularly monitored. Clinical data, including time to death or progression, were collected from the patients' health records. Correlations between absorbed doses by organs and toxicity and between absorbed doses by lesions and tumor volume variation were studied using regression models.

Results

In total, 35 dosimetric studies were performed in patients with mostly grade 2 (77%) tumors and metastases in liver (89%), lymph nodes (77%), and bone (34%), and 146 lesions were analyzed: 1-9 lesions per patient, mostly liver metastases (65%) and lymph nodes (25%). The median total absorbed dose by tumors was 94.4 Gy. The absorbed doses by tumors significantly decreased between cycles. The absorbed dose by tumors was significantly associated with tumor volume variation (P < 0.001) 3 mo after treatment end, and it was a significant prognostic factor for survival. Toxicity analysis showed a correlation between the decrease of hematologic parameters such as lymphocytes or platelet concentrations and the absorbed doses by the spleen or bone marrow. The mean absorbed dose by the kidneys was not correlated with nephrotoxicity during the studied period.

Conclusion

In patients treated with [177Lu]Lu-DOTATATE for GEP-NETs, tumor and healthy organ dosimetry can predict survival and toxicities, thus influencing clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotidePancreatic NeoplasmsOrganometallic CompoundsStomach NeoplasmsIntestinal NeoplasmsPrecision MedicineRadiometryDose-Response Relationship, RadiationHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEabsorbed dose–response relationshipneuroendocrine tumors

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatate

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
  • Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France.
  • Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
  • Department of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France.
  • IBMM, Université de Montpellier, CNRS, ENSCM, Montpellier, France; and.
  • Centre Hospitalier Métropole Savoie, Chambéry, France.

Zitieren

APA

Hebert, K., Santoro, L., Monnier, M., Castan, F., Berkane, I., Assénat, E., Fersing, C., Gélibert, P., Pouget, J. P., Bardiès, M., Kotzki, P. O., & Deshayes, E. (2024). Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. Journal of Nuclear Medicine, 65(6), 923-930. https://doi.org/10.2967/jnumed.123.267023

Vancouver

Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Assénat E, et al. Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. Journal of Nuclear Medicine. 2024;65(6):923-930. doi:10.2967/jnumed.123.267023

BibTeX
@article{Hebert2024,
  author = {Hebert, Kévin and Santoro, Lore and Monnier, Maeva and Castan, Florence and Berkane, Ikrame and Assénat, Eric and Fersing, Cyril and Gélibert, Pauline and Pouget, Jean-Pierre and Bardiès, Manuel and Kotzki, Pierre-Olivier and Deshayes, Emmanuel},
  title = {Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {6},
  pages = {923--930},
  doi = {10.2967/jnumed.123.267023}
}
Kostenlos starten →